Corient Private Wealth
ABBV icon

Corient Private Wealth’s AbbVie ABBV Stock Holding History

Corient Private Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$479M Sell
2,203,650
-2,687,628
-55% -$596M 0.68% 22
2025
Q4 		$1.08B Buy
4,891,278
+2,544,812
+108% +$580M 0.73% 21
2025
Q3 		$543M Sell
2,346,466
-28,544
-1% -$5.81M 0.86% 19
2025
Q2 		$441M Buy
2,375,010
+84,965
+4% +$15.8M 0.59% 26
2025
Q1 		$480M Sell
2,290,045
-43,870
-2% -$8.53M 0.78% 21
2024
Q4 		$414M Buy
2,333,915
+56,369
+2% +$10.4M 0.69% 25
2024
Q3 		$450M Sell
2,277,546
-31,721
-1% -$5.92M 0.7% 27
2024
Q2 		$396M Buy
2,309,267
+194,691
+9% +$32.3M 0.69% 26
2024
Q1 		$385M Sell
2,114,576
-66,316
-3% -$11.4M 0.69% 31
2023
Q4 		$338M Buy
2,180,892
+151,900
+7% +$22.1M 0.62% 33
2023
Q3 		$302M Sell
2,028,992
-1,140
-0.1% -$167K 0.7% 28
2023
Q2 		$273M Buy
2,030,132
+423,005
+26% +$62M 0.63% 32
2023
Q1 		$256M Buy
1,607,127
+467,514
+41% +$71.5M 0.69% 31
2022
Q4 		$184M Buy
+1,139,613
New +$175M 0.67% 31

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corient Private Wealth's ABBV Position: Q1 2026 in Review

Corient Private Wealth reduced its AbbVie (ABBV) stake by 55% in Q1 2026, selling an estimated $596M and leaving 2,203,650 shares worth $479M. The position accounts for 0.68% of the portfolio, ranked #22.

Corient Private Wealth first reported a position in ABBV in Q4 2022 and has held it in 14 quarters since. The position peaked at $1.08B in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Corient Private Wealth held 2,203,650 shares of AbbVie worth $479M as of Q1 2026.
  • Corient Private Wealth sold 2,687,628 AbbVie shares in Q1 2026, an estimated $596M.
  • AbbVie made up 0.68% of Corient Private Wealth's portfolio in Q1 2026, its #22 holding.
  • Corient Private Wealth first reported a position in AbbVie in Q4 2022 and has held it in 14 quarters since.
  • Corient Private Wealth's AbbVie position peaked at $1.08B in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.